PCM
ACAD icon

Prelude Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Prelude Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-50,700
Closed -$774K – 1698
2018
Q2 		$774K Buy
+50,700
New +$904K 0.05% 398
2017
Q3 		– Sell
-32,000
Closed -$892K – 1585
2017
Q2 		$892K Buy
+32,000
New +$954K 0.08% 231
2016
Q4 		– Sell
-15,400
Closed -$490K – 1510
2016
Q3 		$490K Buy
+15,400
New +$522K 0.05% 321
2014
Q1 		– Sell
-700
Closed -$17K – 1821
2013
Q4 		$17K Buy
+700
New +$16.5K ﹤0.01% 1365

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Prelude Capital Management's ACAD Position: Q3 2025 in Review

Prelude Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 27,511 shares — an estimated $593K sold.

Prelude Capital Management first reported a position in ACAD in Q2 2013 and held it in 10 quarters. The position peaked at $1.05M in Q2 2013. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Prelude Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 27,511 Acadia Pharmaceuticals shares in Q3 2025, an estimated $593K.
  • Prelude Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • Prelude Capital Management's Acadia Pharmaceuticals position peaked at $1.05M in Q2 2013.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.